Search Results 751-760 of 18572 for Relapse
A midterm analysis of a multisite phase 1 study of cevostamab for relapsed or refractory multiple myeloma (RRMM) finds the drug safe and tolerable with deep ...
They often attempt to stop without any assistance; unfortunately, relapse rates are greater than 95 percent with such an approach. Dr. McFadden's work has ...
The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...
... relapse rates at other centers. He continues to investigate those psychosocial factors positively impacting sobriety and outcomes after a transplant. Impact ...
... relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ...
A Study of R-ICE and Lenalidomide for Treating Patients with First-Relapse ... relapsed or refractory diffuse large B-cell lymphoma (DLBCL) receiving ...
Gertz studies relapse rates in patients with multiple myeloma and amyloidosis when being treated with novel versus traditional therapies. Focus areas.
Understanding who is more likely to have a relapse of lymphoma and why. Finding ways to improve quality of life after lymphoma treatment. Publications. See a ...
The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...
Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Cancer. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.